FDAnews

THE MEDICINES COMPANY ENROLLS PATIENTS IN CANGRELOR TRIAL

The Medicines Company has reported that patients have been enrolled in Phase III clinical trials evaluating cangrelor, a medicine for preventing platelet activation and aggregation during the clotting process.

If the trials are successfully completed and cangrelor receives regulatory clearance, the company believes cangrelor will be the first IV platelet inhibitor to market that binds directly to the P2Y12 receptor.

The Phase III program is comprised of two multinational trials to evaluate cangrelor's effectiveness and safety in preventing ischemic events in patients who require percutaneous coronary intervention.